Sanofi SA (SNY)

40.52
0.14 0.36
NYSE : Health Care
Prev Close 40.66
Open 40.67
Day Low/High 40.01 / 40.68
52 Wk Low/High 36.81 / 44.50
Volume 2.56M
Avg Volume 2.62M
Exchange NYSE
Shares Outstanding 2.57B
Market Cap 105.31B
EPS 1.90
P/E Ratio 21.99
Div & Yield 1.66 (4.10%)

Latest News

Actelion Surges on Report of Sanofi Challenge to J&J Takeover Bid

Actelion Surges on Report of Sanofi Challenge to J&J Takeover Bid

Actelion shares are on the rise again on reports of a potential counter-bid from France's Sanofi.

Sanofi Genzyme Announces Start Of Phase III Study Of Isatuximab For Relapsed And Refractory Multiple Myeloma

Sanofi Genzyme Announces Start Of Phase III Study Of Isatuximab For Relapsed And Refractory Multiple Myeloma

Sanofi Genzyme, the specialty care global business unit of Sanofi, today announced the initiation of the ICARIA-MM Phase III trial of isatuximab, an investigational anti-CD38 monoclonal antibody being studied for the...

Actelion Shares Fall Sharply on Report It Is Resisting $17 Billion J&J Takeover

Actelion Shares Fall Sharply on Report It Is Resisting $17 Billion J&J Takeover

Actelion shares traded sharply lower Tuesday following reports it's looking at strategies that would keep it independent from a $17 billion approach from Johnson & Johnson.

Amicus Tumbles on Lengthy Delay to U.S. Fabry Drug FDA Filing Plan

Amicus Tumbles on Lengthy Delay to U.S. Fabry Drug FDA Filing Plan

The U.S. Food and Drug Administration turned down Amicus' request to seek accelerated approval for Galafold based on an existing kidney biomarker data.

New Survey Finds Men In The U.S. Want To Take Charge Of Their Own Health And Wellness

New Survey Finds Men In The U.S. Want To Take Charge Of Their Own Health And Wellness

Data also Shows Men Consider Sexual Health to be an Important Priority

Dow, Lifted by Financials, Finishes at Record High; Nasdaq Slips

Dow, Lifted by Financials, Finishes at Record High; Nasdaq Slips

Wall Street runs at two speeds as a rally in financials sent the Dow Jones Industrial Average to close at records, while a selloff in tech sank the Nasdaq.

Dow Hits New Records, Nasdaq Falls as Tech Stocks Decline

Dow Hits New Records, Nasdaq Falls as Tech Stocks Decline

Wall Street remains divided on Thursday as investors try to gauge the types of policies president-elect Donald Trump could enact.

MannKind Is Still Too Heavy to Avoid the Afrezza Crash Landing

MannKind Is Still Too Heavy to Avoid the Afrezza Crash Landing

MannKind bulls -- the rainbow-hued unicorns of the investment world -- believe the company's marketing efforts will succeed. They're wrong.

Here's Which Pharma Giants Might Want to Buy Pfizer's Consumer Health Unit

Here's Which Pharma Giants Might Want to Buy Pfizer's Consumer Health Unit

A sale or spinoff of this business will likely get the attention of competitors that want to increase their over-the-counter product units.

S&P 500, Nasdaq Turn Red in Erratic Post-Election Trading

S&P 500, Nasdaq Turn Red in Erratic Post-Election Trading

Wall Street runs at two speeds on Thursday with the Dow Jones Industrial Average setting a record high and the S&P 500 and Nasdaq slipping.

Stock Futures Rise as Wall Street Rally Continues After Trump's Win

Stock Futures Rise as Wall Street Rally Continues After Trump's Win

Stock futures move higher on Thursday with the Dow Jones Industrial Average set to open at a high.

Donald Trump Election Victory Boosts Some Stocks and Sectors

Donald Trump Election Victory Boosts Some Stocks and Sectors

As we all know, the stock market and the economy abhor uncertainty.

5 Things You Must Know Before the Market Opens Wednesday

5 Things You Must Know Before the Market Opens Wednesday

Stock futures are tumbling Wednesday but are well off their lows as Republican Donald Trump is elected the next president of the United States in a surprising victory.

European Drug Companies Get an Injection From Trump Victory

European Drug Companies Get an Injection From Trump Victory

The threat of a government clampdown on drug prices is off the table with Clinton's defeat, while wider support for defensive stocks helped push pharmaceuticals higher.

Gilead Sciences' Next Challenge to Incyte's Myelofibrosis Drug Dominance

Gilead Sciences' Next Challenge to Incyte's Myelofibrosis Drug Dominance

Gilead Sciences is nearing the completion of two phase III studies of the Jak inhibitor momelotinib in myelofibrosis, a disease affecting bone marrow.

Alexion Soars, Then Falls Amid Takeover Rumors

Alexion Soars, Then Falls Amid Takeover Rumors

The biotech company cancelled its conference appearance and took its time filing its Form 10-Q with the Securities and Exchange Commission.

Sanofi Genzyme Begins Pivotal Phase 3 Trial Of NeoGAA Investigational Second-Generation Therapy For Pompe Disease

Sanofi Genzyme Begins Pivotal Phase 3 Trial Of NeoGAA Investigational Second-Generation Therapy For Pompe Disease

Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today that the first patient has been enrolled and received an infusion in a pivotal Phase 3 clinical trial named COMET for the...

The Internet of Things Is Transforming Healthcare, but There's One Huge Risk

The Internet of Things Is Transforming Healthcare, but There's One Huge Risk

Tech giants, Big Pharma and insurers are all angling to profit from the $3 trillion-plus U.S. healthcare market.

Closing Bell: Regeneron Slides on FDA Ruling; FBI Reopens Clinton Case

Closing Bell: Regeneron Slides on FDA Ruling; FBI Reopens Clinton Case

It was a volatile end to the week after federal investigators reopened a case into Hillary Clinton's email server.

European Stocks Mixed on Divergence in Economic Data, Mixed Earnings

European Stocks Mixed on Divergence in Economic Data, Mixed Earnings

Economic data in France disappoints; Germany and U.K. beat expectations.

Buy Drug Maker Sanofi After It Surpassed Third-Quarter Estimates

Buy Drug Maker Sanofi After It Surpassed Third-Quarter Estimates

The pharmaceutical company reported better-than-expected results on Friday morning. Grab its ADRs now.

European Stocks Slip After French GDP Miss; Novo Nordisk Plunges on U.S. Woes

European Stocks Slip After French GDP Miss; Novo Nordisk Plunges on U.S. Woes

Pharma group Sanofi rises on improved guidance and RBS gains after a third-quarter profit beat.

What to Look for When Sanofi (SNY) Reports Q3 Results

What to Look for When Sanofi (SNY) Reports Q3 Results

Analysts are expecting to see a year-over-year decline in earnings and revenue when Sanofi (SNY) posts 2016 third-quarter results before Friday's market open.

New Survey Reveals The Widespread And Serious Impact Of Moderate-to-Severe Atopic Dermatitis On People Living With The Disease

New Survey Reveals The Widespread And Serious Impact Of Moderate-to-Severe Atopic Dermatitis On People Living With The Disease

U.S. adults report issues with sleep, ability to work and feelings of depression and anxiety